Reduced initial Pazopanib dosing strategy for recurrent, advanced, or metastatic sarcoma: A single center experience
Journal of Oncology Pharmacy Practice
Published online on March 21, 2026
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
IntroductionPazopanib is a treatment option for patients who have advanced or metastatic soft tissue sarcoma. Although the FDA label recommends pazopanib 800 mg q24h as the initial dose, the starting dose in clinical practice can range from 200 mg to 800 ...
IntroductionPazopanib is a treatment option for patients who have advanced or metastatic soft tissue sarcoma. Although the FDA label recommends pazopanib 800 mg q24h as the initial dose, the starting dose in clinical practice can range from 200 mg to 800 ...